Sermorelin

GRF (1–29)-NH₂; GHRH (1–29) amide

Identity

Sequence

YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2

Three-letter

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

Length

29 residues

Modifications

C-terminal amide

Formula

C149H246N44O42S

Average mass

3357.9 Da

CAS

86168-78-7

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

The 1–29 amide fragment of human growth-hormone-releasing hormone, the shortest fully active GHRH sequence. GHRH-receptor reference agonist. Formerly marketed as a drug (Geref); that product was discontinued and no sermorelin drug is currently authorized in Canada or the United States.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.